I doubt the current standard of care of suppressing HBV DNA to undetectable levels, will change. On combos, in addition, I think the benefit on patients achieving viral suppression is too low and studies will have to prove that a combo is superior to sequential monotherapy. So not a great chance for this to gain traction either, imo.
Market Data 
Markets 
AI
